Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

PRODUCT NAME

QUEENSLAND NITRATES PRILLED AMMONIUM NITRATE

NFPA

PRODUCT USE

Major component of explosives, blasting agents. May explode if containers are heated.

SYNONYMS

"nitrate of ammonia in prill form", "nitric acid, ammonium salt", prilled, "ammonium(1)
nitrate(1:1)"

Section 2 - HAZARDS IDENTIFICATION

CANADIAN WHMIS SYMBOLS

EMERGENCY OVERVIEW

RISK

Risk of explosion by shock, friction, fire or other sources of ignition.
Contact with combustible material may cause fire.
Irritating to eyes.
Harmful to aquatic organisms.

POTENTIAL HEALTH EFFECTS

ACUTE HEALTH EFFECTS

SWALLOWED

  Although ingestion is not thought to produce harmful effects, the material may still be damaging to the health of the individual following ingestion, especially where pre-  existing organ (e.g. liver, kidney) damage is evident. Present definitions of harmful or toxic substances are generally based on doses producing mortality (death) rather than those producing morbidity (disease, ill-health). Gastrointestinal tract discomfort may produce nausea and vomiting. In an occupational setting however, ingestion of insignificant quantities is not thought to be cause for concern.  Considered an unlikely route of entry in commercial/industrial environments.  The substance and/or its metabolites may bind to hemoglobin inhibiting normal uptake of oxygen. This condition, known as "methemoglobinemia", is a form of oxygen starvation (anoxia).  Symptoms include cyanosis (a bluish discoloration skin and mucous membranes) and breathing difficulties. Symptoms may not be evident until several hours after exposure.  At about 15% concentration of blood methemoglobin there is observable cyanosis of the lips, nose and earlobes. Symptoms may be absent although euphoria, flushed face and headache are commonly experienced. At 25-40%, cyanosis is marked but little disability occurs other than that produced on physical exertion. At 40-60%, symptoms include weakness, dizziness, lightheadedness, increasingly severe headache, ataxia, rapid shallow respiration, drowsiness, nausea, vomiting, confusion, lethargy and stupor. Above 60% symptoms include dyspnea, respiratory depression, tachycardia or bradycardia, and convulsions. Levels exceeding 70% may be fatal.  

EYE

  This material can cause eye irritation and damage in some persons.  

SKIN

  The material is not thought to produce adverse health effects or skin irritation following contact (as classified using animal models). Nevertheless, good hygiene practice requires that exposure be kept to a minimum and that suitable gloves be used in an occupational setting.  Bare unprotected skin should not be exposed to this material.  The material may accentuate any pre-existing dermatitis condition.  

INHALED

  There is some evidence to suggest that this material, if inhaled, can irritate the throat and lungs of some persons.  Although inhalation is not thought to produce harmful effects, the material may still produce health damage, especially where pre-existing organ (e.g. liver, kidney) damage is evident. Present definitions of harmful or toxic substances are generally confined to doses producing mortality (death) rather than those producing morbidity (disease, ill-  health).  

CHRONIC HEALTH EFFECTS

  Principal routes of exposure are by accidental skin and eye contact andinhalation of generated dusts.  A few individuals may show allergic/sensitization responses which may be minor to severe. Exposure will aggravate this pre-existing condition and those with sensitization reactions should not be required to work where exposure may occur.  As with any chemical product, contact with unprotected bare skin; inhalation of vapor, mist or dust in work place atmosphere; or ingestion in any form, should be avoided by observing good occupational work practice.